About: Chapter sixteen Peptide Nanomedicines for Treatment of Acute Lung Injury

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chapter sixteen Peptide Nanomedicines for Treatment of Acute Lung Injury Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chapter sixteen Peptide Nanomedicines for Treatment of Acute Lung Injury
Creator	Sadikot, Ruxana
source	Elsevier; Medline; PMC
abstract	Abstract Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients. Despite the increased understanding of the molecular pathogenesis of ARDS, the mortality remains unacceptably high, ranging from 34% to 64%. Hence, ARDS represents an unmet medical need with an urgency to develop effective pharmacotherapies. Several promising targets that have been identified as potential therapies for ARDS have been limited because of difficulty with delivery. In particular, delivery of peptides and proteins to the lung is an ongoing challenge. Nanobiotechnology and nanoscience are the basis of innovative techniques to deliver drugs targeted to the site of inflamed organs, such as the lungs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and pharmakodynamics of agents allowing an increase in the biodistribution of therapeutic agents to target organs, resulting in improved efficacy with reduction in drug toxicity. These systems are exploited for therapeutic purpose to carry the drug in the body in a controlled manner from the site of administration to the therapeutic target. Hence, it is an attractive strategy to test potential targets for ALI/ARDS using nanotechnology. To this end, we have identified several potential targets and proposed the delivery of these agents using nanomicelles to improve the drug delivery.
has issue date	2012-12-31(xsd:dateTime)
bibo:doi	10.1016/b978-0-12-391860-4.00016-1
bibo:pmid	22449933
has license	els-covid
sha1sum (hex)	acb84758409b4744b6e71479df137ee0113cb10e
schema:url	https://doi.org/10.1016/b978-0-12-391860-4.00016-1
resource representing a document's title	Chapter sixteen Peptide Nanomedicines for Treatment of Acute Lung Injury
has PubMed Central identifier	PMC7149708
has PubMed identifier	22449933
schema:publication	Methods in Enzymology
resource representing a document's body	covid:acb84758409b4744b6e71479df137ee0113cb10e#body_text
is schema:about of	named entity 'Injury' named entity 'Lung' named entity 'ACUTE LUNG INJURY' named entity 'PEPTIDE' named entity 'TREATMENT' named entity 'Acute Lung Injury' named entity 'extravasation' named entity 'peptide' named entity 'lung inflammation' named entity 'dermal' named entity 'Hsp90' named entity 'molecular weight' named entity 'biodegradable' named entity 'drug delivery systems' named entity 'pattern recognition receptors' named entity 'lung inflammation' named entity 'ALI' named entity 'range of applications' named entity 'ARDS' named entity 'renal clearance' named entity 'amphipathic' named entity 'cytokine' named entity 'nanoparticles' named entity 'bioactivity' named entity 'protein' named entity 'critically ill patients' named entity 'NF-kB' named entity 'acute lung injury' named entity 'Pison' named entity 'biodegradable' named entity 'peptide' named entity '17-AAG' named entity 'pulmonary capillary' named entity 'hydrophobic core' named entity 'signaling molecules' named entity 'amphipathic' named entity 'systemic administration' named entity 'ARDS' named entity 'lipid' named entity 'long-acting' named entity 'polymers' named entity 'nanoparticles' named entity 'lungs' named entity 'inflammation' named entity 'DSPE' named entity 'biodegradable' named entity 'severe acute respiratory syndrome' named entity 'tumor' named entity 'nanomedicines' named entity 'ARDS' named entity 'nanotechnology' named entity 'ARDS' named entity 'biocompatibility' named entity 'inflammation' named entity 'specific sites' named entity 'lungs' named entity 'Nanoparticulate' named entity 'reactive oxygen species' named entity 'therapeutic agents' named entity 'glucagon-like peptide-1' named entity 'biodegradable' named entity 'organ' named entity 'nanoparticles' named entity 'HIV' named entity 'aerosolized' named entity 'LPS' named entity 'long-acting' named entity '17-AAG' named entity 'medical application' named entity 'lyophilized' named entity 'microvessels' named entity 'alveoli' named entity 'mouse model' named entity 'respiratory diseases' named entity 'extravasation' named entity 'proinflammatory' named entity 'ROS' named entity 'polyethylene glycol' named entity 'drug delivery' named entity 'drug delivery systems' named entity 'receptor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software